Bicara Therapeutics (BCAX) Shares Outstanding (2023 - 2026)

Bicara Therapeutics' Shares Outstanding (Entity) history runs 4 years deep, the most recent figure standing at $65.5 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 20.21% year-over-year to $65.5 million; the TTM figure through Mar 2026 stood at $65.5 million (up 20.21% YoY), while the FY2025 annual figure was $54.7 billion, up 225.35% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $65.5 million, down from $54.7 billion in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $54.7 billion in Q4 2025, with the low at $579975.0 in Q3 2023.
• The 4-year median for Shares Outstanding (Entity) is $54.6 million (2025), against an average of $6.6 billion.
• The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Entity) soared 8415.02% in 2025, then grew 20.21% in 2026.
• Bicara Therapeutics' Shares Outstanding (Entity) stood at $580.1 million in 2023, then surged by 2796.96% to $16.8 billion in 2024, then jumped by 225.35% to $54.7 billion in 2025, then slumped by 99.88% to $65.5 million in 2026.
• Business Quant data shows BCAX's Shares Outstanding (Entity) at $65.5 million in Q1 2026, $54.7 billion in Q4 2025, and $54.6 million in Q3 2025.